Sato, M.; Odagiri, K.; Tabuchi, Y.; Okamoto, H.; Shimokawa, T.; Nakamura, Y.; Hata, M.
Patterns and Incidence of Pneumonitis and Initial Treatment Outcomes with Durvalumab Consolidation Therapy after Radical Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer. Cancers 2024, 16, 1162.
https://doi.org/10.3390/cancers16061162
AMA Style
Sato M, Odagiri K, Tabuchi Y, Okamoto H, Shimokawa T, Nakamura Y, Hata M.
Patterns and Incidence of Pneumonitis and Initial Treatment Outcomes with Durvalumab Consolidation Therapy after Radical Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer. Cancers. 2024; 16(6):1162.
https://doi.org/10.3390/cancers16061162
Chicago/Turabian Style
Sato, Mizuki, Kazumasa Odagiri, Yuya Tabuchi, Hiroaki Okamoto, Tsuneo Shimokawa, Yukiko Nakamura, and Masaharu Hata.
2024. "Patterns and Incidence of Pneumonitis and Initial Treatment Outcomes with Durvalumab Consolidation Therapy after Radical Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer" Cancers 16, no. 6: 1162.
https://doi.org/10.3390/cancers16061162
APA Style
Sato, M., Odagiri, K., Tabuchi, Y., Okamoto, H., Shimokawa, T., Nakamura, Y., & Hata, M.
(2024). Patterns and Incidence of Pneumonitis and Initial Treatment Outcomes with Durvalumab Consolidation Therapy after Radical Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer. Cancers, 16(6), 1162.
https://doi.org/10.3390/cancers16061162
